Edition:
India

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

19.20USD
2:29am IST
Change (% chg)

$1.02 (+5.61%)
Prev Close
$18.18
Open
$18.21
Day's High
$19.30
Day's Low
$18.21
Volume
124,790
Avg. Vol
89,826
52-wk High
$29.48
52-wk Low
$14.36

Chart for

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology... (more)

Overall

Beta: 2.78
Market Cap(Mil.): $659.43
Shares Outstanding(Mil.): 36.80
Dividend: --
Yield (%): --

Financials

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage:

16 Nov 2017

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

16 Nov 2017

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

09 Nov 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

25 Oct 2017

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules

06 Sep 2017

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

01 Sep 2017

BRIEF-MacroGenics Q2 net loss per share $1.14

* MacroGenics provides update on corporate progress and second quarter 2017 financial results

03 Aug 2017

BRIEF-Boxer Capital reports 5.5 pct passive stake in Macrogenics

* Boxer Capital, Llc reports 5.5 percent passive stake in Macrogenics Inc as of may 31, 2017 -sec filing Source text - http://bit.ly/2sVCckL Further company coverage:

13 Jun 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Amgen, Inc. (AMGN.OQ) $170.00 -0.77
Xencor Inc (XNCR.OQ) $21.35 +0.17

Earnings vs. Estimates